ProPhase Labs, Inc. Sale Leaseback Transaction, Transaction Costs, Investing Activities
ProPhase Labs, Inc. (PRPH) reported Sale Leaseback Transaction, Transaction Costs, Investing Activities of $1.90 million for the 12-month period ending 2017-12-31, per its 10-K filed 2019-03-26.
Discontinued › Cash Flow › Investing Activities
us-gaap:SaleLeasebackTransactionTransactionCostsInvestingActivities · last filed 2019-03-26
- ProPhase Labs, Inc. sale leaseback transaction, transaction costs, investing activities for the quarter ending 2017-12-31 was $0.00.
- ProPhase Labs, Inc. sale leaseback transaction, transaction costs, investing activities for the quarter ending 2017-09-30 was $0.00.
- ProPhase Labs, Inc. sale leaseback transaction, transaction costs, investing activities for the quarter ending 2017-06-30 was $0.00.
- ProPhase Labs, Inc. sale leaseback transaction, transaction costs, investing activities for the quarter ending 2017-03-31 was $1.90M.
- ProPhase Labs, Inc. sale leaseback transaction, transaction costs, investing activities for fiscal 2017 was $1.90M.
| Period end | Sale Leaseback Transaction, Transaction Costs, Investing Activities 3 month | Sale Leaseback Transaction, Transaction Costs, Investing Activities 6 month | Sale Leaseback Transaction, Transaction Costs, Investing Activities 9 month | Sale Leaseback Transaction, Transaction Costs, Investing Activities 12 month |
|---|---|---|---|---|
| 2017-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-26 | $0.00 derived: sum of 2 quarters · filed 2019-03-26 | $0.00 derived: sum of 3 quarters · filed 2019-03-26 | $1.90M 10-K · filed 2019-03-26 |
| 2017-09-30 | $0.00 derived: 10-Q 9 month − 10-Q/A 6 month · filed 2018-11-14 | $0.00 derived: sum of 2 quarters · filed 2018-11-14 | $1.90M 10-Q · filed 2018-11-14 | |
| 2017-06-30 | $0.00 derived: 10-Q/A 6 month − 10-Q/A 3 month · filed 2018-08-20 | $1.90M 10-Q/A · filed 2018-08-20 | ||
| 2017-03-31 | $1.90M 10-Q/A · filed 2018-08-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |